About EDGAR Online | Login
 
The following is an excerpt from a S-1/A SEC Filing, filed by ALGORX PHARMACEUTICALS INC on 12/30/2004.
Next Section Next Section Previous Section Previous Section
ALGORX PHARMACEUTICALS INC - S-1/A - 20041230 - MARKET_RISK

Quantitative and Qualitative Disclosure About Market Risk

      Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because the majority of our investments are in short-term marketable securities. Due to the nature of our short-term investments, we believe that we are not subject to any material market risk exposure. We do not have any foreign currency or other derivative financial instruments.

40